PMID- 24202336
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20131108
LR  - 20211021
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 5
IP  - 3
DP  - 2013 Aug 22
TI  - Emerging biomarkers in glioblastoma.
PG  - 1103-19
LID - 10.3390/cancers5031103 [doi]
AB  - Glioblastoma, the most common primary brain tumor, has few available therapies 
      providing significant improvement in survival. Molecular signatures associated 
      with tumor aggressiveness as well as with disease progression and their relation 
      to differences in signaling pathways implicated in gliomagenesis have recently 
      been described. A number of biomarkers which have potential in diagnosis, 
      prognosis and prediction of response to therapy have been identified and along 
      with imaging modalities could contribute to the clinical management of GBM. 
      Molecular biomarkers including O(6)-methlyguanine-DNA-methyltransferase (MGMT) 
      promoter and deoxyribonucleic acid (DNA) methylation, loss of heterozygosity 
      (LOH) of chromosomes 1p and 19q, loss of heterozygosity 10q, isocitrate 
      dehydrogenase (IDH) mutations, epidermal growth factor receptor (EGFR), epidermal 
      growth factor, latrophilin, and 7 transmembrane domain-containing protein 1 on 
      chromosome 1 (ELTD1), vascular endothelial growth factor (VEGF), tumor suppressor 
      protein p53, phosphatase and tensin homolog (PTEN), p16INK4a gene, cytochrome c 
      oxidase (CcO), phospholipid metabolites, telomerase messenger expression (hTERT 
      messenger ribonucleic acid [mRNA]), microRNAs (miRNAs), cancer stem cell markers 
      and imaging modalities as potential biomarkers are discussed. Inclusion of 
      emerging biomarkers in prospective clinical trials is warranted in an effort for 
      more effective personalized therapy in the future.
FAU - McNamara, Mairead G
AU  - McNamara MG
AD  - Pencer Brain Tumor Centre, Princess Margaret Cancer Centre, 610 University 
      Avenue, Toronto, Ontario M5G 2M9, Canada. warren.mason@uhn.ca.
FAU - Sahebjam, Solmaz
AU  - Sahebjam S
FAU - Mason, Warren P
AU  - Mason WP
LA  - eng
PT  - Journal Article
DEP - 20130822
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC3795381
EDAT- 2013/11/10 06:00
MHDA- 2013/11/10 06:01
PMCR- 2013/08/22
CRDT- 2013/11/09 06:00
PHST- 2013/06/29 00:00 [received]
PHST- 2013/08/14 00:00 [revised]
PHST- 2013/08/19 00:00 [accepted]
PHST- 2013/11/09 06:00 [entrez]
PHST- 2013/11/10 06:00 [pubmed]
PHST- 2013/11/10 06:01 [medline]
PHST- 2013/08/22 00:00 [pmc-release]
AID - cancers5031103 [pii]
AID - cancers-05-01103 [pii]
AID - 10.3390/cancers5031103 [doi]
PST - epublish
SO  - Cancers (Basel). 2013 Aug 22;5(3):1103-19. doi: 10.3390/cancers5031103.